Pharmacogenetic approach to losartan in Marfan patients: a starting point to improve dosing regimen?

Felicia Stefania Falvella, Susan Marelli, Stefania Cheli, Stefano Montanelli, F. Viecca, Lucia Salvi, Alfio Ferrara, Emilio Clementi, Giuliana Trifirò, Alessandro PiniDrug 2016 · DOI

Abstract

The optimal dose of angiotensin receptor blocker is not known, and no data are available about losartan pharmacogenetic profile in Marfan syndrome; we have proposed a strategy to tackle this issue based on evaluating the major genetic polymorphisms involved in the losartan conversion into active carboxylic acid metabolite. Further studies are needed to support the use of genetic polymorphisms as predictors of the right dose of losartan.
BibTeX
@inproceedings{falvella2016pharmacogenetic,
  author = {Felicia Stefania Falvella and Susan Marelli and Stefania Cheli and Stefano Montanelli and F. Viecca and Lucia Salvi and Alfio Ferrara and Emilio Clementi and Giuliana Trifirò and Alessandro Pini},
  title = {{Pharmacogenetic approach to losartan in Marfan patients: a starting point to improve dosing regimen?}},
  booktitle = {Drug},
  year = {2016},
  doi = {10.1515/dmpt-2016-0006},
}

Loading related content...

Figure